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cell transplant recipientsDear Editor,
We read with interest the study by Liu et al1 about the
incidence of proven and probable invasive fungal infection
(IFI) in allogeneic hematopoietic stem cell transplant
(HSCT) recipients. The study demonstrated that the inci-
dence of IFI was 7.4% in patients at a medical center in
Taiwan. An understanding of local IFI epidemiology is
crucial in developing comprehensive antifungal strategies
to treat various at-risk populations.2 However, there is a
lack of data regarding IFI burden in Taiwan. In addition, our
study describes the incidence of invasive mold disease
(IMD) in patients with acute myelogenous leukemia (AML)
who were undergoing first remission-induction chemo-
therapy, and in recipients of HSCT at a cancer center in
Taiwan.
The Koo Foundation Sun Yat-Sen Cancer Center is a 200-
bed cancer hospital that has a dedicated infectious disease
consult service, which is a part of the multidisciplinary
hematology and stem cell transplant program. The hospital
provides routine micafungin prophylaxis for all allogeneic
HSCT recipients but not for patients with AML or for
autologous HSCT recipients. We retrospectively reviewed
medical records from 2010 to 2014 to calculate the inci-
dence of IMD in the following patient populations: (1) AML
patients undergoing first remission-induction chemo-
therapy; (2) autologous HSCT recipients; and (3) allogeneic
HSCT recipients. IMD was diagnosed according to the Eu-
ropean Organization for Research and Treatment of Can-
cer/Invasive Fungal Infections Cooperative Group and the
National Institute of Allergy and Infectious Diseases Myco-
ses Study Group (EORTC/MSG) Consensus Group
definitions.3
In our study, there were 39 AML patients undergoing first
remission-induction chemotherapy, 41 autologous HSCT re-
cipients, and 38 allogeneic HSCT recipients. The incidence
rates of probable and proven IMD in these three groups werePlease cite this article in press as: Yang X-Y, Chen W-T, Burden of invas
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the AML patients undergoing first remission-induction
chemotherapy, the median time from chemotherapy to
IMD was 16 days (range, 9e72 days), and pulmonary infec-
tion was the most common type of IMD (5 pulmonary in-
fections, 1 sinonasal infection, and 1 pulmonary and
sinonasal infection were observed). Among these cases, only
one was documented as being caused by Cladosporium.
Among the allogeneic HSCT recipients, the median time
from HSCT to IMD was 294 days (range, 115e567 days), and
pulmonary infection was the most common type of IMD (3
pulmonary infections, 1 pulmonary and sinonasal infection,
and 1 disseminated infection were observed). Among these
cases, one was documented as being caused by Aspergillus
niger and another by Paceliomyces. The occurrence of IMD in
allogeneic HSCT recipients was associated with relapse of
underlying disease (n Z 4) and the occurrence of graft-
versus-host disease (nZ 1).
We reported that the incidence of IMD was 13.2% in
allogeneic HSCT recipients and demonstrated an even
higher IMD incidence of 17.9% in AML patients undergoing
first induction-remission chemotherapy. Previous studies
have demonstrated various degrees of fungal burden in
these high-risk patient populations, but epidemiological
studies on IFI, and especially on IMD, have been rare in
Taiwan.4,5 Epidemiological data, such as those presented
by our study, are critical for guiding future IFI management
strategies and research in Taiwan.
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